

<b>Statement of Deficiencies</b>	<b>(X1) Provider/Supplier/CLIA Identification Number</b>  17D1052648	<b>(X3) Date Survey Completed</b>  02/03/2023
<b>Name of Provider or Supplier</b>  Kansas Medical Center, Llc	<b>Street Address, City, State</b>  1124 W 21st Street, Andover, KS	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

<b>(X4) ID Prefix Tag</b>	<b>Summary Statement of Deficiencies</b>
<b>D2016</b>	<p><b>SUCCESSFUL PARTICIPATION</b> CFR(s): 493.803(a)(b)(c)</p> <p>(a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history.</p> <p>This CONDITION is not met as evidenced by: Based on the review of proficiency testing (PT) records from American Proficiency Institute (API), the laboratory failed to successfully participate in PT under the specialty Immunohematology for the regulated analyte: Compatibility Testing. (Refer to D2181)</p>
<b>D2181</b>	<p><b>COMPATIBILITY TESTING</b> CFR(s): 493.863(e)</p> <p>Failure to achieve an overall testing event score of satisfactory for two consecutive</p>

testing events or two out of three consecutive testing events is unsuccessful performance.

This STANDARD is not met as evidenced by:

Based upon the review of PT results from API and phone interview, the laboratory failed to successfully participate in PT for the regulated analyte: Compatability Testing. Findings: 1. Review of Second Event 2022 revealed a score of 80% for Compatability Testing. 2. Review of Third Event 2022 revealed a score of 80% for Compatability Testing. 3. The laboratory manager on 2/3/23 at 12:30 pm in phone interview confirmed the laboratory failed to successfully participate in PT for the regulated analyte: Compatability Testing.